Trulicity’s ascent lifts Lilly

The company also recently gained FDA approval for Alimta in combination with Keytruda and platinum chemotherapy for the first-line treatment of patients with metastatic NSCLC with no EGFR or ALK

EMA says Lilly’s Lartruvo should not be prescribed

The product was viewed as an important element in Lilly’s efforts to prop up its oncology franchise after the loss of patent protection for blockbuster Alimta (pemetrexed) in some markets,

Lilly adds to pharma M&A run with $8bn Loxo buy-out

Lilly does have presence in the lung cancer field with Alimta, and as this drug is nearing patent expiry, Loxo should provide the firm with opportunities to seize a share of

Roche’s Tecentriq misses survival mark in frontline NSCLC

Roche’s PD-L1 inhibitor Tecentriq (pemetrexed) was unable to meet the threshold for a significant improvement in overall survival (OS) when added to Eli Lilly’s Alimta (pemetrexed) and platinum

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]